Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC ...